2 completed, 1 unknown. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Type2diabetes: new trials by email Literature Review of Type2diabetes trials Research Report on Type2diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Finerenone and Renal Oxidative Stress Finerenone 20 MG Oral Tablet, Placebo - Type2diabetes | Phase 3 | Completed | University of Erlangen-Nürnberg Medical School | 91 | 2024-01-18 | 2026-04-02 |
| Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control Insulin Glargine 100 UNT/ML Pen Injector [Lantus], Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg, Pioglitazone 30mg - Type2diabetes | Phase 3 | Completed | University of Basrah | 243 | 2023-11-01 | 2025-03-30 |
| Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes Metformin, Dapagliflozin, Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone) - Type2diabetes, Insulin Resistance | Phase 3 | Unknown | Nanjing First Hospital, Nanjing Medical University | 60 | 2022-11-01 | 2022-10-24 |
Glucose Metabolism Disorders (1) · Hyperinsulinism (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
Pioglitazone (2) · Insulin Glargine (1) · Metformin (1) · Tablets (1) · dapagliflozin (1) · finerenone (1) · saxagliptin (1)
Nanjing First Hospital, Nanjing Medical University (1) · University of Basrah (1) · University of Erlangen-Nürnberg Medical School (1)
Germany (1) · Iraq (1)
Dennis Kannenkeril, MD (1) · Haider A Alidrisi, MD (1) · Roland E. Schmieder, MD (1)